Sight Sciences Analyst Ratings
Sight Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 21.95% | Morgan Stanley | $8.4 → $4 | Maintains | Equal-Weight |
| 09/12/2023 | 37.2% | B of A Securities | $10 → $4.5 | Downgrades | Neutral → Underperform |
| 09/12/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 09/12/2023 | 67.68% | Piper Sandler | $15 → $5.5 | Downgrades | Overweight → Neutral |
| 08/24/2023 | 156.1% | Morgan Stanley | $12 → $8.4 | Downgrades | Overweight → Equal-Weight |
| 08/21/2023 | 143.9% | Citigroup | $9 → $8 | Maintains | Neutral |
| 08/04/2023 | 265.85% | Morgan Stanley | $15 → $12 | Maintains | Overweight |
| 07/11/2023 | 174.39% | Citigroup | $15 → $9 | Downgrades | Buy → Neutral |
| 07/10/2023 | 174.39% | Citigroup | $15 → $9 | Downgrades | Buy → Neutral |
| 06/26/2023 | 296.34% | Stifel | $15 → $13 | Maintains | Buy |
| 06/12/2023 | — | Needham | Maintains | Hold | |
| 06/06/2023 | 204.88% | B of A Securities | $13 → $10 | Maintains | Buy |
| 01/06/2023 | 357.32% | Morgan Stanley | $11 → $15 | Maintains | Overweight |
| 01/06/2023 | 357.32% | Stifel | $10 → $15 | Upgrades | Hold → Buy |
| 12/12/2022 | 357.32% | Citigroup | $10 → $15 | Maintains | Buy |
| 11/11/2022 | 235.37% | Morgan Stanley | $10 → $11 | Maintains | Overweight |
| 10/11/2022 | 204.88% | Morgan Stanley | $14 → $10 | Maintains | Overweight |
| 10/04/2022 | — | Needham | Initiates Coverage On | → Hold | |
| 08/12/2022 | 326.83% | Morgan Stanley | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 357.32% | Piper Sandler | $17 → $15 | Maintains | Overweight |
| 07/26/2022 | 204.88% | Stifel | → $10 | Initiates Coverage On | → Hold |
| 07/15/2022 | 418.29% | Morgan Stanley | $18 → $17 | Maintains | Overweight |
| 05/11/2022 | 448.78% | Morgan Stanley | $27 → $18 | Maintains | Overweight |
| 05/11/2022 | 418.29% | Piper Sandler | $23 → $17 | Maintains | Overweight |
| 03/25/2022 | 967.07% | Citigroup | $39 → $35 | Maintains | Buy |
| 02/03/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 723.17% | Morgan Stanley | $36 → $27 | Upgrades | Equal-Weight → Overweight |
| 08/09/2021 | 1271.95% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 08/09/2021 | 1302.44% | Citigroup | → $46 | Initiates Coverage On | → Buy |
| 08/09/2021 | 1150% | Morgan Stanley | → $41 | Initiates Coverage On | → Equal-Weight |
| 08/09/2021 | 1241.46% | Piper Sandler | → $44 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/13/2023 | 21.95% | 摩根士丹利 | $8.4→$4 | 維護 | 等重 |
| 09/12/2023 | 37.2% | B of A證券 | $10→$4.5 | 評級下調 | 中性→表現不佳 |
| 09/12/2023 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 09/12/2023 | 67.68% | 派珀·桑德勒 | $15→$5.5 | 評級下調 | 超重→中性 |
| 2023年08月24日 | 156.1% | 摩根士丹利 | $12→$8.4 | 評級下調 | 超重→等重 |
| 2023年08月21日 | 143.9% | 花旗集團 | $9→$8 | 維護 | 中性 |
| 08/04/2023 | 265.85% | 摩根士丹利 | $15→$12 | 維護 | 超重 |
| 07/11/2023 | 174.39% | 花旗集團 | $15→$9 | 評級下調 | 購買→中性 |
| 07/10/2023 | 174.39% | 花旗集團 | $15→$9 | 評級下調 | 購買→中性 |
| 2023/06/26 | 296.34% | Stifel | $15→$13 | 維護 | 買 |
| 2023/06/12 | - | 李約瑟 | 維護 | 保持 | |
| 06/06/2023 | 204.88% | B of A證券 | $13→$10 | 維護 | 買 |
| 01/06/2023 | 357.32% | 摩根士丹利 | $11→$15 | 維護 | 超重 |
| 01/06/2023 | 357.32% | Stifel | $10→$15 | 升級 | 持有→購買 |
| 2022年12月12日 | 357.32% | 花旗集團 | $10→$15 | 維護 | 買 |
| 2022年11月11日 | 235.37% | 摩根士丹利 | $10→$11 | 維護 | 超重 |
| 2022年10月11日 | 204.88% | 摩根士丹利 | $14→$10 | 維護 | 超重 |
| 10/04/2022 | - | 李約瑟 | 開始承保 | →保留 | |
| 2022年08月12日 | 326.83% | 摩根士丹利 | $17→$14 | 維護 | 超重 |
| 2022年08月12日 | 357.32% | 派珀·桑德勒 | $17→$15 | 維護 | 超重 |
| 07/26/2022 | 204.88% | Stifel | →$10 | 開始承保 | →保留 |
| 07/15/2022 | 418.29% | 摩根士丹利 | $18→$17 | 維護 | 超重 |
| 2022年05月11日 | 448.78% | 摩根士丹利 | $27→$18 | 維護 | 超重 |
| 2022年05月11日 | 418.29% | 派珀·桑德勒 | $23→$17 | 維護 | 超重 |
| 03/25/2022 | 967.07% | 花旗集團 | $39→$35 | 維護 | 買 |
| 02/03/2022 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 01/07/2022 | 723.17% | 摩根士丹利 | $36→$27 | 升級 | 等重→超重 |
| 08/09/2021 | 1271.95% | B of A證券 | →$45 | 開始承保 | →購買 |
| 08/09/2021 | 1302.44% | 花旗集團 | →$46 | 開始承保 | →購買 |
| 08/09/2021 | 1150% | 摩根士丹利 | →$41 | 開始承保 | →等重 |
| 08/09/2021 | 1241.46% | 派珀·桑德勒 | →$44 | 開始承保 | →超重 |
What is the target price for Sight Sciences (SGHT)?
視覺科學(SGHT)的目標價格是多少？
The latest price target for Sight Sciences (NASDAQ: SGHT) was reported by Morgan Stanley on September 13, 2023. The analyst firm set a price target for $4.00 expecting SGHT to rise to within 12 months (a possible 21.95% upside). 18 analyst firms have reported ratings in the last year.
視科(納斯達克代碼：SGHT)的最新目標價是由摩根士丹利於2023年9月13日報道的。這家分析公司將目標價定為4.00美元，預計SGHT將在12個月內上漲至21.95%(可能上漲21.95%)。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Sight Sciences (SGHT)?
視覺科學(SGHT)的最新分析師評級是多少？
The latest analyst rating for Sight Sciences (NASDAQ: SGHT) was provided by Morgan Stanley, and Sight Sciences maintained their equal-weight rating.
視科(納斯達克股票代碼：SGHT)最新分析師評級由摩根士丹利提供，視科維持同等權重評級。
When is the next analyst rating going to be posted or updated for Sight Sciences (SGHT)?
視覺科學(SGHT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sight Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sight Sciences was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Sight Sciences的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。視覺科學的上一次評級是在2023年9月13日提交的，所以你應該預計下一次評級將在2024年9月13日左右提供。
Is the Analyst Rating Sight Sciences (SGHT) correct?
分析師對視覺科學(SGHT)的評級正確嗎？
While ratings are subjective and will change, the latest Sight Sciences (SGHT) rating was a maintained with a price target of $8.40 to $4.00. The current price Sight Sciences (SGHT) is trading at is $3.28, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的視覺科學(SGHT)評級維持不變，目標價在8.40美元至4.00美元之間。Sight Sciences(SGHT)目前的股價為3.28美元，超出了分析師的預測區間。